Gilead Sciences
GILD
$0.65 (0.72%)
1D
1W
3M
1Y
5Y
ALL
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • 2 days ago • GILD
Gilead Sciences, Inc. (GILD) Jefferies London Healthcare Conference (Transcript)
Benzinga • 7 days ago • GILD
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Business Wire • 7 days ago • GILD
Gilead's Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
Zacks Investment Research • 8 days ago • GILD
Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet
Zacks Investment Research • 8 days ago • GILD
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.
